Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2020 1
2023 2
2024 2
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI).
Sharma A, Kaiser PK, Tadayoni R, Holz FG, Nicholson L, Vazquez-Alfageme C, Sivaprasad S, Wakabayashi T, Woo SJ, Sarraf D, Kumar N, Parachuri N, Regillo CD, Rezaei KA, Khanani AM, Bandello F, Shanamugam M, Verma L, Dogra MR, Ns M, Agarwal M, Loewenstein A, Kuppermann BD; International Retina Biosimilar Study Group (Inter BIOS Group). Sharma A, et al. Eye (Lond). 2024 Dec;38(17):3392-3395. doi: 10.1038/s41433-024-03284-x. Epub 2024 Aug 26. Eye (Lond). 2024. PMID: 39187656 No abstract available.
Biosimilar ranibizumab (BS1) - early experience from Japan (BRIJ study).
Ueda-Consolvo T, Ishida M, Nakamura T, Yanagisawa S, Tsuboi K, Wakabayashi T, Hayashi A, Sharma A; International Retina Biosimilar Study Group (Inter BIOS Group). Ueda-Consolvo T, et al. Eye (Lond). 2024 Nov;38(16):3193-3196. doi: 10.1038/s41433-024-03220-z. Epub 2024 Jul 23. Eye (Lond). 2024. PMID: 39043816 No abstract available.
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey).
Sharma A, Holz FG, Regillo CD, Freund KB, Sarraf D, Khanani AM, Baumal C, Holekamp N, Tadayoni R, Kumar N, Parachuri N, Kuppermann BD; International Retina Biosimilar Study Group (Inter BIOS Group); International Retina Biosimilar Study Group (Inter BIOS Group); Bandello F, Querques G, Loewenstein A, Özdek Ş, Rezai K, Laurent K, Bilgic A, Lanzetta P, Zur D, Yannuzzi N, Corradetti G, Kaiser P, Hilely A, Boyer D, Rachitskaya A, Chakravarthy U, Wintergerst M, Sarao V, Parolini B, Mruthyunjaya P, Nguyen QD, Do D, Keane PA, Hassan T, Sridhar J, Eichenbaum D, Grewal D, Splitzer M. Sharma A, et al. Expert Opin Biol Ther. 2023 Jul-Dec;23(8):851-859. doi: 10.1080/14712598.2023.2176218. Epub 2023 Feb 19. Expert Opin Biol Ther. 2023. PMID: 36726203
FYB-201 Biosimilar ranibizumab (Ongavia/Ranivisio/Cimerli) Efficacy and Safety in Clinical Settings - FORCE study.
Sharma A, Nicholson L, Vazquez-Alfageme C, Sivagnanavel V, Fausto R, Soare MC, Salamanca MB, Fabozzi L, Tsika C, Corbalan OC, Verdejo AG, Wakabayashi T, Woo SJ, Kolomeyer AM, Mansour H, Momenaei B, Regillo CD; International Retina Biosimilar Study Group (Inter BIOS Group). Sharma A, et al. Eye (Lond). 2025 Oct 2. doi: 10.1038/s41433-025-04030-7. Online ahead of print. Eye (Lond). 2025. PMID: 41039072